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ABSTRACT
Pancreatic ductal adenocarcinoma is the most common form of
pancreatic tumour, with a very limited survival rate and currently no
available disease-modifying treatments. Despite recent advances
in the production of genetically engineered mouse models
(GEMMs), the development of new therapies for pancreatic
cancer is still hampered by a lack of reliable and predictive
preclinical animal models for this disease. Preclinical models are
vitally important for assessing therapies in the first stages of the
drug development pipeline, prior to their transition to the clinical
arena. GEMMs carry mutations in genes that are associated
with specific human diseases and they can thus accurately mimic
the genetic, phenotypic and physiological aspects of human
pathologies. Here, we discuss different GEMMs of human
pancreatic cancer, with a focus on the Lox-Stop-Lox (LSL)-
KrasG12D; LSL-Trp53R172H; Pdx1-cre (KPC) model, one of the
most widely used preclinical models for this disease. We describe
its application in preclinical research, highlighting its advantages
and disadvantages, its potential for predicting clinical outcomes in
humans and the factors that can affect such outcomes, and, finally,
future developments that could advance the discovery of new
therapies for pancreatic cancer.
KEY WORDS: Co-clinical trials, Preclinical mouse models,
Pancreatic ductal adenocarcinoma, PDAC, Drug discovery,
Drug development
Introduction
Pancreatic cancers are a group of diseases that affect both the
endocrine and exocrine compartments of the pancreas. The most
common of these is pancreatic ductal adenocarcinoma (PDAC), an
exocrine malignancy that accounts for >90% of all cases of
pancreatic cancer (Feldmann and Maitra, 2008; Warshaw and
Fernandez-del Castillo, 1992). PDAC is a lethal disease, with a
5-year survival rate of <5% (Hidalgo, 2010), and is the fourth leading
cause of cancer-related deaths in the United States, with 48,960 new
cases and 40,560 deaths estimated in 2015 (Siegel et al., 2015;
Warshaw and Fernandez-del Castillo, 1992). In the United
Kingdom, it is the fifth most common cause of cancer-related
mortality, with 8773 newly diagnosed cases in 2011 and 8662 deaths
in 2012 (Cancer Research UK, http://www.cancerresearchuk.org/
cancer-info/cancerstats/types/pancreas/; accessed August 2015).
In humans, the most frequent genetic alteration that underlies
PDAC is an activating mutation of the KRAS oncogene (see Box 1),
which occurs in >90% of tumours (Almoguera et al., 1988; Biankin
et al., 2012). In addition, inactivation of the cyclin-dependent kinase
inhibitor 2A (CDKN2A) locus, point mutations in tumour protein
p53 (TP53) and mutations or deletions of SMAD (Sma/mothers
against decapentaplegic) family member 4 (SMAD4) are commonly
found in PDAC tumours (see Box 1) (Hruban et al., 2001b). Disease
progression occurs through a series of pre-invasive pancreatic
intraepithelial neoplasia (PanIN), which are graded according to
their severity of dysplasia and nuclear atypia (see Box 2) (from
PanIN-1, the least severe grade, to PanIN-3, which is considered
ductal carcinoma in situ and is the last grade before invasive
carcinoma). These neoplasia grades are also well replicated in
animal models (Fig. 1) (Hruban et al., 2001a, 2004). Histologically,
PDACs are primarily glandular, although sarcomatoid, colloid and
adenosquamous (see Box 2) tumours also occur (Hruban and
Adsay, 2009). These tumours are characterized by a dense
desmoplastic stroma, consisting of extracellular matrix proteins –
such as collagens, laminin and fibronectin – together with
fibroblasts and immune cells (Adler, 2004). Early dissemination is
also a common feature of PDAC, with primary tumours exhibiting
perineural, vascular and lymphoid invasion (Hezel et al., 2006).
The poor prognosis associated with PDAC can mostly be
attributed to the lack of its early detection. At first diagnosis, most
affected individuals present with advanced and metastatic disease,
with less than 20% of patients diagnosed with resectable tumours
(Heestand et al., 2015). Metastatic pancreatic cancer is associated
with a median survival of less than 6 months on gemcitabine-based
chemotherapy (Hidalgo, 2010) (Box 2). Gemcitabine was approved
as a standard of care for treating this cancer because it provided
a modest survival benefit and improvements in quality of
life, compared to treatment with another chemotherapeutic,
5-fluorouracil, in a Phase 3 study (Burris et al., 1997) (Box 2).
More recently, Phase 3 studies have demonstrated that the
chemotherapy combinations of FOLFIRINOX (Fluorouracil/
Oxaliplatin/Leucovorin/Irinotecan) and gemcitabine/nanoparticle
albumin-bound (nab)-paclitaxel (see Box 2), result in improved
survival over treatment with gemcitabine alone (Conroy et al., 2011;
Goldstein et al., 2015; Von Hoff et al., 2013). In late 2013,
the combination of gemcitabine and nab-paclitaxel was approved
by the Food and Drug Administration (FDA) in the United States
for the first-line treatment of metastatic PDAC. Although
FOLFIRINOX and gemcitabine/nab-paclitaxel are promising
recent developments in the treatment of PDAC, their benefit in
terms of survival is limited to months, and therefore there is still a
need to develop other novel drugs and combinations to treat this
disease.
Novel therapies are identified through the drug discovery and
development process, which is outlined in Fig. 2. In this process, the
preclinical phase acts as a bridge to the clinic, allowing promising
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compounds identified at earlier stages to be tested for their
pharmacology, toxicity and efficacy. The successful evaluation of
therapies in the preclinical setting greatly depends on the robustness
and predictive ability of preclinical models, which include both
in vitro and in vivo systems (Fig. 2). However, tumour complexity is
not accounted for in in vitro systems, although co-culture models
have been developed that, for instance, involve culturing cancer
cells with fibroblasts, immune cells or endothelial cells (Wilding
and Bodmer, 2014). In vitro drug testing also does not account for
the effect of pharmacokinetics and drug metabolism on the activity
of a compound nor for its toxicity. Historically, in vivo anti-cancer
drug evaluation has been carried out in xenograft models (see
Box 2), which can be easily and rapidly generated in
immunodeficient mice by the implantation of tumour cells or of
tissues into ectopic or orthotopic sites (Richmond and Su, 2008).
More recently, patient-specific xenografts, which replicate features
of individual patient tumours, have been developed to evaluate
personalized treatment options (Rubio-Viqueira et al., 2006; Shu
et al., 2008; Siolas and Hannon, 2013). Although of lower cost
to generate, useful for higher throughput approaches, and
complementary to genetically engineered models in comparing
mouse and human tumours, xenograft models lack a functional
immune system, and produce tumours of reduced complexity and
cellular diversity, which could contribute to the fact that drug test
results obtained in xenograft systems (as well as in in vitro systems)
do not correlate well with efficacy testing in humans. In fact, only a
small percentage of cancer patients in Phase 1 clinical trials respond
to therapies as predicted (Roberts et al., 2004). The disparity
between preclinical data and clinical studies can be attributed to
various factors, including differences in pharmacokinetics,
pharmacodynamics and metabolism, as well as a failure to
accurately model the tumour microenvironment (Becher and
Holland, 2006; Gopinathan and Tuveson, 2008; Sharpless and
Depinho, 2006; Zhang et al., 2013). In pancreatic cancer, in
particular, tumours are demonstrably stromal in nature, and the
complex interactions between tumour and stromal cells might alter
Box 2. Glossary of terms
Adenosquamous: refers to a cancer type containing both gland-like
cells and squamous cells (very thin, flattened cells).
Anaplastic: cells with abnormal morphology and loss of ordered
orientation, compared to normal differentiated cells.
Cachexia: a wasting syndrome characterized by loss of weight, fat and
muscle mass that is not reversed nutritionally.
CD3: a cell surface molecule that associates with the T-cell receptor to
allow its activation. The presence of CD3 on the surface of all T cells at all
stages of development makes it a good marker for T cells in tissue
sections.
Colloid: glue like – refers to highly mucinous tumours (mucins are
glycoproteins found in secretions).
CRISPR/Cas: a system used for gene editing and gene regulation.
The Cas9 protein causes DNA breaks, and CRISPRs (clustered
regularly interspaced short palindromic repeats) are stretches of DNA
with a spacer that target a specific gene. Delivery of CRISPR guide
RNAs and Cas9 into a cell allows the genome to be cut at the desired
location.
Dysplasia: the enlargement of a tissue or organ by the proliferation of
abnormal cells.
Flp-FRT recombinase system: a site-specific recombination system
used to control the spatial expression of transgenes. It consists of
flippase (Flp) recombinase, which targets FLP recombinase target (FRT)
sequences that are placed at either end of a gene or region of interest.
Fluorouracil: an antimetabolite chemotherapeutic agent that is a
pyrimidine analogue that irreversibly inhibits the nucleotide synthetic
enzyme thymidylate synthase.
Gemcitabine: a deoxycytidine analogue used as the standard of care for
pancreatic cancer. It is activated by phosphorylation, and the di- and tri-
phosphate forms are responsible for its cytotoxicity. It inhibits
ribonucleotide reductase, and also competes with deoxycytidine
5-triphosphate (dCTP) for incorporation into DNA during replication. It
causes DNA damage and induces apoptosis.
Haemorrhagic ascites: the accumulation of blood-stained fluid in the
peritoneum.
Irinotecan: a cytotoxic chemotherapeutic that inhibits topoisomerase 1,
resulting in inhibition of DNA replication and transcription.
Laparotomy: a surgical incision in the abdominal wall to gain access into
the abdominal cavity.
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): a paclitaxel
formulation that uses albumin, the main protein of human blood plasma,
to bind paclitaxel and to facilitate its transport out of the bloodstream and
into the tumour. Studies show that this formulation increases the
therapeutic efficacy of paclitaxel compared to its conventional
formulation.
Nuclear atypia: abnormal cell nuclei, e.g. often by size, shape or
staining pattern.
Oxaliplatin: a platinum-based chemotherapeutic agent. It leads to
cross-linking of DNA, thereby inhibiting DNA synthesis and transcription.
Sarcomatoid: a histological tumour subtype characterized by spindle-
shaped tumour cells.
Transposon (or transposable element): a short DNA sequence that
can alter its position within the genome, thereby causing genetic
changes.
Xenograft: model generated by the injection or implantation of human
cancer cells or tissues into ectopic or orthotopic sites to generate
tumours in immunocompromised mice.
Box 1. Commonly mutated genes in human pancreatic
cancer
KRAS (Kirsten rat sarcoma viral oncogene homolog)
The KRAS gene encodes a protein that plays an essential role in cell
signalling in normal tissue, through its activity as an ‘on/off’ switch for
many signal transduction pathways, particularly those regulating cell
division. Activating mutations in pancreatic tumorigenesis cause Kras to
be constitutively active, which makes cells grow and divide in an
uncontrolled manner.
CDKN2A (cyclin-dependent kinase inhibitor 2A)
The CDKN2A locus is responsible for encoding two tumour suppressor
proteins: p16INK4a and p14ARF. p16INK4a blocks aberrant cell growth and
division. Inactivating mutations thus allow cells to grow and divide in an
uncontrolled manner. p14ARF protects the p53 tumour suppressor
protein from being degraded (see below).
TP53 (tumour protein p53), inactivating point mutation
p53 is a tumour suppressor protein that stops cells from dividing too fast,
or causes damaged or mutated cells that might otherwise become
tumour cells to undergo apoptosis (cell suicide). It is often mutated in
pancreatic tumours, meaning that mutated cells do not undergo
apoptosis and that unregulated cell division occurs instead.
SMAD4 (Sma/mothers against decapentaplegic family member 4),
inactivating mutation or deletion
The SMAD4 protein is a transcription factor (it regulates transcription of
other genes) activated by signalling from the membrane-bound TGFβ
(transforming growth factor beta) protein. The TGFβ pathway carries
signals from the extracellular environment to the nucleus and affects how
cells respond to such signals by inducing the production of new proteins.
SMAD4 deletions in pancreatic tumorigenesis can cause cells to
proliferate in an uncontrolled manner.
BRCA2 (breast cancer 2, early onset)
TheBRCA2 gene encodes the breast cancer type 2 susceptibility protein
(BRCA2). It is essential for the repair of double-stranded DNA breaks by
homologous recombination, and its loss results in chromosomal
instability.
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the efficacy of therapeutic agents. The desmoplastic stroma might
also act as a barrier to the delivery of agents, such as gemcitabine
(Olive et al., 2009), or as a source of survival cues that confer
resistance to therapy (Vonlaufen et al., 2008; Xu et al., 2014).
Genetically engineered mouse models (GEMMs) offer an
alternative to in vitro and xenograft models, and are currently
being used to study tumour biology and responses to therapy. Mice
are the preferred species for genetic manipulation because of their
genetic tractability and because mice carry 99% of the same genes
as humans (Mouse Genome Sequencing et al., 2002). GEMMs
exist for several epithelial tumour types, including prostate, lung,
breast, colon and pancreatic cancers (Frese and Tuveson, 2007).
They are generally developed through the introduction of genetic
mutations either in oncogenes or tumour suppressors that are
associated with specific tumour types, often using conditional
strategies that allow for tissue-specific regulation of these genes.
GEMMs can therefore faithfully recapitulate some human cancers
in terms of their genetics and phenotype. They can thus be used to
study tumour biology, initiation and progression, and to test the
action and efficacy of anti-cancer drugs at various time points
during disease progression.
In this Review, we describe different GEMMs of pancreatic
cancer and their utility for understanding the progression of PDAC
and for identifying therapeutic targets. We focus in particular on
one of the most widely used GEMMs of pancreatic cancer, the
LSL-KrasG12D; LSL-Trp53R172H; Pdx1-cre (KPC) model, and its
use in the preclinical testing of anti-cancer agents. Finally, we
discuss the importance of GEMMs in translating research findings
to the clinic, and highlight their limitations and potential
opportunities for their improvement.
F PDAC G Liver met E PanIN-3 
C PanIN-1B D PanIN-2 B Normal duct 
100µm 
100µm 100µm 100µm 
Pancreas-specific Cre  
(e.g. Pdx1-Cre )  
loxP loxP
STOP
loxP  loxP
1*LSL-KrasG12D
LSL-Trp53R172H STOP1 2 5*43
1*
1 2 5*43
A Absence of Cre Cre expression
Fig. 1. Progression of pancreatic cancer in the KPC model recapitulates the human disease. (A) In KPC mice, the conditional expression of mutant
KrasG12D and Trp53R172H is controlled by a pancreas-specificCre (Pdx1-cre in themodel described here). In the absence of Cre, a transcriptional and translational
STOP cassette flanked by loxP sites (LSL) silences the expression of mutant KrasG12D and Trp53R172H. When Cre is expressed in the pancreas, the STOP
cassette is excised and the mutant alleles are expressed. The coloured boxes represent exons, and the asterisk (*) indicates the exon in which the mutation is
present. The concomitant expression of mutant Kras and Trp53 in the murine pancreas results in pre-invasive pancreatic intraepithelial neoplasia (PanIN), which
progress to pancreatic ductal adenocarcinoma (PDAC). (B) Haematoxylin and eosin (H&E) staining of normal pancreatic ducts in wild-typemice showing that they
consist of a single layer of flat, low cuboidal epithelial cells with basal nuclei (arrows). (C-G) H&E staining in KPCmice. (C) In PanIN-1B, papillary or micropapillary
projections develop in the ducts (arrows), otherwise these lesions are similar to PanIN-1A (not shown here). (D) More advanced PanIN-2 is characterized by
nuclear abnormalities, including loss of polarity (black and white arrows), nuclear overcrowding, enlarged nuclei and rare mitoses (white arrow). (E) PanIN-3,
ductal carcinoma in situ, is the highest grade of neoplasm and is associated with several abnormalities, including: papillary architecture with loss of nuclear
polarity; occasional aberrant mitoses; nuclear abnormalities; large prominent nucleoli; and cribriforming (small clusters of epithelial cells budding into the lumen
and necrosis in the lumen) (arrows). (F) PDAC, the resulting carcinoma, exhibits a glandular phenotype with duct-like structures of varying degrees of
differentiation, and can exhibit adenosquamous or sarcomatoid histology. Substantial nuclear abnormalities occur and glands appear embedded in the tumour
stroma (arrowheads) with completely random organization (arrows). Tumour cells can be observed next to arteries, with perineural and vascular invasion often
seen. Necrotic debris can be seen in the lumen of the gland. (G) In advanced disease, metastatic spread is common, particularly to the liver (Liver met).
Metastases often exhibit a glandular histology similar to well-differentiated PDAC. Arrow shows a metastatic deposit in mouse liver.
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GEMMs of pancreatic cancer: unravelling cancer
mechanisms
Many GEMMs of pancreatic cancer have been created (see Table 1)
and several feature the deletion or introduction of a mutation into a
relevant tumour suppressor gene, often in the context of an
activating mutation in Kras (see Box 1). Although mutations in
Kras are a requisite event in the initiation of pancreatic disease,
additional genetic events are required to induce tumour formation.
Knockout studies have been conducted in the context of mutant
Kras, with and without additional tumour suppressor mutations,
revealing the role of these additional mutations in pancreatic tumour
development. These studies have shown, for example, that
mutations in Trp53 and loss of the Cdkn2a locus or Smad4
accelerate PDAC development in the context of mutant Kras (see
Box 1), but with differing histologies (Aguirre et al., 2003;
Bardeesy et al., 2006; Izeradjene et al., 2007). Monoallelic Trp53
loss accelerates tumour development with the same kinetics as
mutant Trp53R172H, but mutant Trp53R172H also drives metastatic
behaviour in pancreatic tumours (Morton et al., 2010c). When
Brca2 (see Box 1) is deleted in the presence of an activating Kras
mutation, PDAC formation is suppressed owing to chromosomal
instability and apoptosis (Rowley et al., 2011). However, when
Trp53 and Brca2 are both deleted, mice are more likely to develop
PDAC, at reduced latency (Rowley et al., 2011). Moreover, in the
absence of functional p53, Brca2 deletion can cooperate with
activated Kras mutation to drive pancreatic tumorigenesis (Morton
et al., 2011; Rowley et al., 2011; Skoulidis et al., 2010). These
studies in GEMMs highlight that human PDAC-associated genetic
mutations drive PDAC progression, in cooperation with mutant
Kras, and are not simply bystander mutations.
In addition to the genes mentioned above, several proteins and
pathways have been identified that either promote or suppress PDAC
progression, and their effects on tumour development have been
studied, some of which are summarized in Table 2. Other GEMMs
have shed light on the development of different histological subtypes
of the disease. For instance, cystic lesions of the pancreas, such as
intraductal papillary mucinous neoplasms (IPMNs) and mucinous
cystic neoplasms (MCNs), occur in humans and can progress to
invasive cancer if untreated. GEMMs have shown that loss of
transcriptional intermediary factor 1 gamma (TIF1γ) or brahma-
related gene-1 (Brg1) results in cystic lesions in the pancreas (Vincent
et al., 2009; von Figura et al., 2014). TIF1γ is a nuclear protein, the
molecular function of which is poorly understood, with existing
evidence suggesting that it might regulate TGFβ signalling positively
and negatively (Dupont et al., 2005; Dupont et al., 2009; He et al.,
2006). Brg1 is the catalytic ATPase component of the SWI/SNF
chromatin remodelling complexes, and is therefore involved in gene
transcriptional regulation, with evidence suggesting that it acts as a
tumour suppressor in a variety of human cancers (Wong et al., 2000;
Izeradjene et al., 2007; Vincent et al., 2009; von Figura et al., 2014).
Although candidate gene approaches such as those described above
have provided valuable information about the associations between
individual genes and specific PDAC phenotypes, forward genetic
screens such as those based on the use of transposon-mediated
mutagenesis (see Box 2) have also helped to identify previously
unknown pathways of potential relevance in tumour development in
an unbiased manner (Mann et al., 2012; Perez-Mancera et al., 2012).
Despite their advantages, these models are not without some
limitations. For example, mutant genes may be expressed in the
entire pancreas through the use of embryonic pancreatic promoters
such as Pdx-1 and p48 (Hingorani et al., 2003, 2005; Westphalen
and Olive, 2012), but the leakiness of these promoters may result in
off-target pathologies in other tissues (Gades et al., 2008; Hingorani
et al., 2003, 2005). There is, therefore, a need to develop improved
GEMMs of PDAC that overcome such limitations. Recently, an
inducible KrasG12D model has been developed that allows for the
conditional and reversible expression of oncogenic Kras in the
pancreas (Collins et al., 2012a; Ying et al., 2012). This model has
been used to study the role of activated Kras in maintaining
established tumours, and the mechanisms by which it acts (Collins
et al., 2012a,b; Ying et al., 2012). Indeed, results obtained from this
model have identified the activation of Yap1 (Yes-associated
Target
identification
and validation
Lead
identification  
Lead
optimization  
Preclinical
testing  
Clinical trials  
Phase 1-2 trials              
Drug discovery Drug development 
Pharmacology
Safety and toxicity
Efficacy
 
 
Cell lines 
2-dimensional 
3-dimensional 
Xenografts
Subcutaneous
Orthotopic
Patient-derived
GEMMs 
Phase 3 
Fig. 2. Schema of the drug discovery and development pipeline. The initial stages of the pipeline focus on the discovery and validation of newly identified
disease-associated drug targets. Target validation is carried out using in vitro and in vivo approaches to confirm the relevance of the target in the disease being
studied. This is followed by the identification of lead compounds through high-throughput or focused screens of chemical libraries or of naturally occurring
molecules, or by structure-based rational drug design. The next stage is lead optimization, where the identified compound is subjected to chemical modifications
to improve its pharmacological properties. Optimized lead compounds are then carried forward into preclinical testing, where pharmacology, toxicity and
efficacy are assessed. Preclinical testing can occur in vitro, in 2- or 3-dimensional cell culture assays, or in vivo, in either xenografts or animal models, including
genetically engineered mouse models (GEMMs). Promising therapies identified here are taken forward into the clinic. Preclinical models thus provide a bridge to
the clinic, and are a requisite part of the drug development pipeline. For more detailed descriptions of the different stages of this pipeline, we refer readers to
several recent reviews (Herter-Sprie et al., 2013; Hughes et al., 2011; Kamb et al., 2007; Kenakin, 2003; Pritchard et al., 2003).
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protein 1) – a transcriptional co-activator in the Hippo pathway that
controls cell proliferation, apoptosis and thus organ size, and is
frequently overexpressed and activated in different cancers (Zhang
et al., 2014) – as a potential bypass mechanism to overcome the
dependence of PDAC on oncogenic Kras (Kapoor et al., 2014).
Although this model is useful, it is important to note that the
inducible Kras is encoded by a transgene, therefore resulting in an
extra copy of Kras not driven from the endogenous promoter.
Another recently published model has made use of the alternate
Flp-FRT recombinase system (see Box 2). Thus far, the genetic
studies carried out in GEMMs of PDAC have involved germline
knockouts or Cre-dependent alleles that are expressed/deleted at
the same time as the initiating oncogenic events. These approaches
interfere with tumour initiation and progression; therefore,
preventative rather than therapeutic approaches are modelled by
gene modulation. The Flp-FRT recombinase system will enable the
generation of GEMMs inwhich the activation or deletion of genes of
interest is under the control of different enzymes, and therefore
more amenable to individual manipulation (DeCant et al., 2014;
Schönhuber et al., 2014). Indeed, Kras activation and Trp53 deletion
Table 1. Genetically engineered mouse models of pancreatic cancer
Name Mutation Phenotype References
KC model: KrasG12D; Cre Oncogenic Kras Full spectrum of pre-invasive PanIN, progressing to
invasive and metastatic PDAC at low frequency
Hingorani et al.,
2003
KPC models: KrasG12D;
Trp53mutant; Cre
Oncogenic Kras; heterozygous Trp53
mutation
Pancreatic cancer with 100% penetrance, with all the
associated features of the disease, including
metastases to the liver, diaphragm and lungs,
cachexia, and haemorrhagic ascites
Hingorani et al.,
2005
KrasG12D; Trp53flox; Cre Oncogenic Kras; heterozygous
deletion of Trp53
Pancreatic cancer with a median survival similar to that
of KPC mice. Lack of metastasis compared to KPC
mice
Morton et al.,
2010c
KPPC models: KrasG12D;
Trp53flox/flox; Cre or
KrasG12D; Trp53mut/mut; Cre
Oncogenic Kras; homozygous
mutations or deletions of the Trp53
allele
Very rapid tumour development; greatly reduced
median survival (usually ∼60 days) compared with
that of mice carrying heterozygous deletion or
mutation of Trp53; multifocal tumours, jaundice,
ascites and local invasion occur; metastasis is not a
common feature
Morton et al.,
2010c
KrasG12D; TGF-βR2flox; Cre Oncogenic Kras; homozygous
deletion of Tgfbr2
Does not impede pancreatic development; rapidly
accelerates the development of well-differentiated
pancreatic cancer with associated weight loss,
haemorrhagic ascites and jaundice; metastatic
spread is common, particularly to the liver
Ijichi et al., 2006
KrasG12D; Cdkn2aflox; Cre Oncogenic Kras; homozygous or
heterozygous deletion of the
Cdkn2a locus (encodes p16 and
p19ARF)
Results in rapid tumour development and replicates
several clinical features of PDAC; local invasion is
extensive but, similar to the KPPC models,
metastasis is not a common feature; heterozygous
Cdkn2a loss extends the latency of tumour
progression and increases the likelihood of
metastasis; histologically, there is a higher number of
sarcomatoid, undifferentiated tumours in models
with disruption of the Cdkn2a locus
Aguirre et al., 2003;
Bardeesy et al.,
2006
KrasG12D; Ptenflox; Cre Oncogenic Kras; heterozygous Pten
loss
Dramatically accelerates PanIN and tumour
development, with a median survival of 3.5 months;
tumours are locally invasive, but metastasis in this
model is relatively rare
Hill et al., 2010;
Kennedy et al.,
2011
KrasG12V; Elastase-tTA/
tetO-Cre
±Ink4a/Arfflox
±Trp53flox
Expression of oncogenic KrasG12V;
deletion of the Cdkn2a locus or of
Trp53 can also be added
Expression of oncogenic KrasG12V in acinar and
centroacinar pancreatic cells during embryogenesis
results in the formation of PanINs that progress to
PDAC; expression in adult mice, however, results in
tumorigenesis only in the context of chronic
pancreatitis; deletion of either theCdkn2a locus or of
Trp53 accelerates disease progression
Guerra et al., 2007;
Guerra et al.,
2011
Elastase-tva; Cdkn2a−/−
+RCAS-PyMT/cMyc
Deletion of the Cdkn2a locus;
expression of Myc or PyMT
Viral delivery of specific oncogenes to ‘acinar’ and
‘centroacinar cells’ in neonatal mice induces different
tumour types; PyMT induces pancreatic acinar or
ductal carcinomas, whereas Myc induces
exclusively endocrine tumours, suggesting targeting
of one or more types of multipotent progenitor cells
Lewis et al., 2003
The models listed in this table are a sample of mouse PDAC models. In particular, they include those that are driven by the most commonly occurring genetic
alterations in human pancreatic cancer, and those that are used for assessing therapeutic agents. The expression of these genes is driven by pancreas-specific
Cre alleles.
RCAS, replication-competent ASLV long terminal repeat (LTR) with a splice acceptor; tva, tumour virus A; PyMT, polyoma middle T antigen; tTA, tetracycline
transactivator protein.
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Table 2. Proteins and signalling pathways contributing to pancreatic cancer development
Name Function Impact on PDAC development References
Ataxia telangiectasia
mutated (ATM)
Serine/threonine kinase involved in DNA-
damage repair, particularly of DNA double-
strand breaks
ATM deletion in the KC model increases
neoplastic changes in the pancreas,
enhances epithelial-to-mesenchymal
transition (EMT) via modulation of TGFβ
signalling and decreases survival
Russell et al., 2015
B-cell-specific Moloney
murine leukaemia virus
insertion site 1 (BMI1)
Member of the polycomb group of repressor
proteins, and is involved in the regulation of
histone ubiquitylation and gene repression
Conditional knockout of Bmi1 in the KC
background abrogates PanIN formation
independent of Cdkn2a status. Bmi1
knockdown in PDAC cell lines results in
impaired detoxification of reactive oxygen
species
Bednar et al., 2015
Cathepsin B A ubiquitously expressed lysosomal protease
belonging to the cysteine cathepsin family,
and is involved in a number of normal
biological processes, including protein
turnover, apoptosis and extracellular-matrix
remodelling. Upregulated in a number of
human malignancies, and is often
mislocalized to the plasma membrane and
secreted in the extracellular space
Cathepsin B loss decreases PanIN burden
and PanIN proliferation in the context of
oncogenic Kras. In the KPCmodel, the loss
of cathepsin B increases survival and
decreases liver metastasis
Gopinathan et al., 2012
c-Jun N-terminal protein
kinase (JNK)
JNK proteins are members of the mitogen
activated protein kinase (MAPK) family, and
are activated by growth factors, cytokines,
G-protein coupled receptor (GCPR)
agonists and environmental stresses. They
regulate various functions, including cell
growth, survival and apoptosis
Two of the direct activators of JNK are MAPK
kinase 4 (MKK4) and MKK7. Conditional
deletion of MKK4 and MKK7 in the murine
pancreas impairs acinar regeneration and
accelerates Kras-driven tumorigenesis
Davies et al., 2014
Endothelial nitric oxide
synthase (eNOS)
Constitutively expressed protein that
generates nitric oxide from the oxidation of
L-arginine. It is regulated by transcriptional
and post-translational modifications
Variable levels of eNOS expression are seen
in PanIN and PDAC. eNOS ablation
decreases mutant Kras-driven PanIN
development, and results in a trend towards
increased survival of mice in the KPC
background
Lampson et al., 2012
Hedgehog (Hh) signalling The Hh pathway is important in development,
during which it regulates cell growth and
survival, cell fate, and body patterning. In
the absence of Hh, signalling is inhibited by
Patched (Ptc) binding to the Smoothened
(Smo) receptor. Hh binds to Ptc to relieve
the inhibition of Smo, resulting in activation
of the Gli transcription factor family. The
pathway is activated inappropriately in
many cancer types
Loss of Gli1 inhibits PanIN progression and
PDAC development in the context of mutant
Kras. Conversely, Gli1 loss in the context of
Kras and Trp53mutations promotes tumour
progression and decreases survival.
Inhibition of Smo was initially thought to
extend survival in combination with
gemcitabine. However, further work
showed that Hh signalling, via its effect on
the tumour stroma, restrains tumours and
inhibition of the pathway accelerates
tumour growth
Lee et al., 2014; Mills
et al., 2013; Mills
et al., 2014; Rhim
et al., 2014
Liver kinase B1 (LKB1 or
STK11)
Originally identified as a tumour suppressor
gene associated with Peutz-Jeghers
syndrome. It is a serine-threonine kinase
and regulates cell growth and metabolism in
response to nutrient changes, by
phosphorylating adenine monophosphate-
activated protein kinase (AMPK)
Lkb1 heterozygosity accelerates PDAC in KC
mice. Uniquely, homozygous deletion of
Lkb1 in the pancreas is sufficient to initiate
tumour development, in the absence of
another initiating oncogenic event.
Mechanistically, Lkb1 deficiency decreases
the expression of the two tumour
suppressor proteins p53 and p21 in PanIN
lesions
Hezel et al., 2008;
Morton et al., 2010a
Lysyl oxidase (LOX) Extracellular copper-dependent enzyme that
cross-links collagen and elastin, increasing
tissue stiffness. It is thought to play a role in
metastasis in some epithelial cancers
Overexpression of LOX is associated with
poor prognosis in patients. In the KPC
model, LOX family members are
overexpressed in metastatic disease. LOX
knockdown decreases PDAC cell invasion
in vitro. Treatment of KPCmice with an anti-
LOX antibody slows tumorigenesis in
combination with gemcitabine and
decreases metastasis
Miller et al., 2015
Continued
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Table 2. Continued
Name Function Impact on PDAC development References
N-cadherin Calcium-dependent glycoprotein belonging to
the cadherin superfamily. Stimulates the
migration and invasion of cells, and its
aberrant expression in cancer cells
increases their motility and invasiveness
Heterozygous, but not homozygous,
N-cadherin loss in the KPC model
increases survival
Su et al., 2012
Notch signalling Crucial for cell fate decisions in development.
The four notch genes encode cell surface
receptors. Ligand binding to the receptors
results in proteolytic cleavage to release the
Notch intracellular domain (NICD), which
translocates to the nucleus, binds the DNA-
binding protein CSL and induces
transcription of Notch target genes,
including Hes and Hey. Aberrant activation
of the Notch pathway contributes to
oncogenesis
Notch2 and Hes1 are upregulated during
PanIN development in Kras mutant
pancreata. Ablation of Notch2, but not
Notch1, halts PanIN progression, results in
mucinous cystic neoplasm (MCN)-like
lesions in the pancreas, and increases
survival. Therapeutic inhibition of Notch
signalling causes vascular regression,
inducing tumour hypoxia and widespread
necrosis, even in the absence of improved
gemcitabine delivery
Mazur et al., 2010;
Cook et al., 2012
Nuclear factor erythroid 2-
related factor 2 (Nrf2)
Nrf2 is a basic leucine zipper transcription
factor that regulates the expression of
antioxidant genes in response to cellular
stressors, thereby controlling levels of
reactive oxygen species (ROS). Although
activation of Nrf2 protects against damage
and awide range of diseases, it is increased
in, and can aid the progression of, several
types of cancer
Nrf2 deletion results in decreased PanIN
formation in Kras-mutant pancreata, with
existing PanIN demonstrating decreased
proliferation and increased senescence
compared to Nrf2-expressing PanIN
DeNicola et al., 2011
Nuclear factor kappa-light-
chain-enhancer of
activated B cells (NF-κB)
NF-κB proteins are transcription factors
involved in a large number of physiological
processes such as growth, apoptosis,
inflammatory responses and development.
They are activated in a number of
malignancies. NF-κB is negatively
regulated by interaction with the inhibitor of
IκB kinase (Ikk) complex
Deletion of IKK2 in the pancreas in the context
of oncogenic Kras inhibits PanIN
progression
Maniati et al., 2011
Phosphatase and tensin
homolog (Pten)
Negatively regulates the phosphoinositide 3-
kinase (PI3K)–protein kinase B (Akt)–
mechanistic target of rapamycin (mTOR)
signalling pathway, which controls cell
metabolism, growth and proliferation, and,
as such, is deregulated in many cancers
Deletion of Pten in the context of oncogenic
Kras accelerates pancreatic tumorigenesis
Hill et al., 2010;
Kennedy et al., 2011
Retinoblastoma (Rb) Tumour suppressor protein. It binds and
inhibits the E2F transcription factors,
thereby preventing G1-S cell cycle
progression. Its function is dysregulated in
several cancers
Deletion of Rb cooperates with oncogenic
Kras to drive early PanIN and mucinous
cystic neoplasm (MCN) development, rapid
progression to PDAC, and decreased
survival. Rb deletion is associated with
inflammatory infiltrates in the pancreas and
dysregulation of p53
Carriere et al., 2011
Signal transducer and
activator of transcription 3
(STAT3)
STAT proteins are typically tyrosine-
phosphorylated by Janus-activated kinases
(JAKs) in response to cytokines and growth
factors. STAT3 plays an important role in the
regulation of inflammation, stem-cell self-
renewal and cancer. Constitutive activation
of STAT3 has been reported in PDAC cell
lines, as well as in human PDAC specimens
STAT3 activation occurs at multiple stages of
Kras-induced pancreatic tumorigenesis. Its
deletion in the murine pancreas decreases
oncogenic-Kras-induced acinar-to-ductal
metaplasia and PanIN formation, and its
knockdown decreases orthotopic PDAC
tumour growth and proliferation.
Conversely, aberrant Stat3 activation in
the pancreas accelerates tumour
development
Corcoran et al., 2011
Sma/mothers against
decapentaplegic family
member 4 (SMAD4/
DPC4)
Smad4 is a tumour suppressor belonging to
the Smad family. It mediates signals from
the transforming growth factor beta (TGFβ)
pathway and suppresses epithelial cell
growth
Heterozygous deletion ofSmad4 concomitant
with oncogenic Kras in the pancreas
induces mucinous cystic neoplasms
(MCNs). Homozygous Smad4 loss
accelerates progression of MCNs, but with
less invasion and metastasis than in the
KPC model
Izeradjene et al., 2007;
Whittle et al., 2015
Continued
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can be temporally separated in the pancreas using a combination of
the Cre-lox and Flp-FRT systems. In Pdx1-Flp; FSF-KrasG12D/+;
FSF-R26CAG−CreERT2/+; Trp53lox/lox mice (KPF), the deletion of
Trp53 2 months after the expression of oncogenic Kras in the
pancreas induces rapid multifocal tumour development
(Schönhuber et al., 2014). The Flp-FRT system was also used to
show that Pdpk1 (3-phosphoinositide-dependent protein kinase 1)
deletion in mutant-Kras-expressing pancreata blocks PanIN
progression (Schönhuber et al., 2014). An alternative method for
generating mouse models uses the CRISPR/Cas (clustered regularly
interspaced short palindromic repeats/CRISPR-associated proteins)
gene-editing system (see Box 2) to mutate tumour suppressor genes
directly in vivo, thereby obviating the need for embryonic stem cell
targeting (Sanchez-Rivera et al., 2014; Xue et al., 2014). This
approach has recently been demonstrated in the pancreas, where
CRISPR-mediated targeting of liver kinase B1 (Lkb1) in mice led to
tumour growth in conjunction with oncogenic Kras, phenocopying
the effect of genetic deletion of Lkb1 (Chiou et al., 2015). In
this study, the authors also induced PDAC development in the
murine pancreas by administering adenoviral-Cre and lentiviral-Cre
to express oncogenic Kras and delete Trp53 (Chiou et al., 2015),
rather than by the widely used transgenic or knock-in Cre alleles
mentioned above.
GEMMS have also proven their utility in preclinical settings. In
particular, they can be used to study how particular genetic lesions
influence responses to therapies, thereby potentially identifying
specific patient populations that might benefit from treatment. For
instance, our group has used the Kras; Ptenmouse model, in which
tumours have high levels of mTOR (mammalian target of
rapamycin) signalling, to test the efficacy of an mTOR inhibitor
(Morran et al., 2014). Inhibitors of mTOR signalling have failed in
clinical trials of all-comers in pancreatic cancer, where patients are
not selected based on the presence of specific mutations. However,
cases of efficacy have been reported when patients have mutations
in the mTOR pathway (Morran et al., 2014), and our findings
support these results and suggest that specific patients might benefit
from treatment with these inhibitors. Inhibition of hedgehog
signalling, a pathway involved in the generation of the tumour
stroma, has been studied in the Kras; Ink4/Arfflox; Cre model,
in which it increases survival (see Table 1) (Feldmann et al., 2008).
In addition, the Kras; Tgfbr2flox; Cre pancreatic cancer model
(see Table 1) has been used to assess the efficacy of the
EGFR (epidermal growth factor receptor) inhibitor erlotinib, as
well as the effect of cancer-associated fibroblast depletion. The
depletion of cancer-associated fibroblasts accelerates pancreatic
cancer development and decreases survival in this model
(Miyabayashi et al., 2013; Ozdemir et al., 2014). The response to
a given therapeutic or genetic intervention might vary in PDAC
models carrying different genetic alterations. For instance, EGFR
ablation prevents tumour development in the background ofCdkn2a
deletion, but only delays it when p53 is lost (Navas et al., 2012), and
erlotinib in Kras; Tgfbr2flox; Cre mice increases survival in
combination with gemcitabine, as described above (Miyabayashi
et al., 2013). Taken together with the studies mentioned above, the
use of GEMMs carrying different genetic alterations to assess
therapeutic targets and agents might be a useful approach to identify
subsets of patients who are likely to respond to specific therapies.
The above is a very brief summary of some of the studies done
using GEMMs of pancreatic cancer (Guerra and Barbacid, 2013),
because an exhaustive discussion of this subject is beyond the scope
of this Review. In the next sections, we describe in greater detail the
KPC model and its use in preclinical settings because it represents
the most common GEMMof PDAC used in this context.We discuss
important insights that have emerged from such studies, as well as
their clinical relevance and limitations.
KPC model: its uses for testing novel cancer therapies
Traditionally, KPC mice are generated by the concomitant
expression of oncogenic KrasG12D and of Trp53 harbouring a
conditional point mutation (Trp53R172H), both driven by a pancreas-
specific Cre, the Pdx1-cre transgene, which is expressed in all cells
of the pancreas from an early stage of embryonic development
(Fig. 1A). KPC mice were first described in 2005 (Hingorani et al.,
2005). These mutant mice develop the complete spectrum of pre-
invasive PanIN, as well as end-stage pancreatic cancer (Fig. 1B-G)
with 100% penetrance and with a much shorter latency relative to
Table 2. Continued
Name Function Impact on PDAC development References
Concomitant Kras and Trp53 mutation with
Dpc4 deletion results in PDAC with the
classical PanIN-to-PDA progression.
However, the metastatic burden in these
mice remains low compared with KPC
mice. The Runx3 transcription factor was
identified as a driver of metastasis in PDAC
Tumour necrosis factor-
related apoptosis-
inducing ligand (TRAIL)
Pro-apoptotic ligand belonging to the tumour
necrosis factor (TNF) superfamily. Binding
of TRAIL to its receptors induces apoptosis
via death-inducing silencing complexes
(DISCs), leading to caspase activation
Conditional deletion of TRAIL-receptor
(TRAIL-R) decreases PanIN burden in the
KC model, and increases survival and
decreases metastasis in KPCmice. Loss of
TRAIL-R results in decreased activation of
Rac1 in tumour cells
von Karstedt et al.,
2015
Ubiquitin specific peptidase
9, X-linked (USP9X)
Deubiquitinase that regulates the stability of
several proteins, including β-catenin, E-
cadherin, Notch, mTOR, MCL1, Itch and
Smad4. It therefore impacts on a number of
cellular processes, including survival,
apoptosis, polarity and chromosome
segregation
Usp9X was identified in a forward genetic
screen using sleeping beauty transposon-
mediated insertional mutagenesis in the KC
background. Loss of Usp9X promotes
transformation and protects pancreatic
cancer cells from anoikis (a form of
programmed cell death) in vitro. Deletion of
Usp9X in the KC model accelerates
pancreatic tumour development
Perez-Mancera et al.,
2012
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models that express oncogenic KrasG12D alone (Hingorani et al.,
2003). The KPC model also exhibits the clinical features of
advanced disease, including loss of body conditioning resembling
cachexia, haemorrhagic ascites (see Box 2), and metastases to the
liver, lungs, peritoneum and lymph nodes (Hingorani et al., 2005).
Histopathologically, the tumours tend to be highly stromal with
dense desmoplasia and a high degree of chromosomal instability,
but sarcomatoid and anaplastic histologies also occur (see Box 2)
(Hingorani et al., 2005). A single mouse can have a tumour with
different histological components but this considerable intra- and
inter-tumour heterogeneity recapitulates that seen in the human
disease. As with other GEMMs, the KPC model is a useful tool to
advance our understanding of pancreatic cancer biology,
particularly given its genetic and histological similarity to the
human disease. In addition, it is probably the most widely used of all
GEMMs in evaluating preclinical therapeutic agents. In this
Review, the term ‘KPC’ is used to refer primarily to mice
harbouring the Trp53R172H mutation and the Pdx1-cre transgene
as described above. However, different Trp53 mutations, such as
Trp53R270H, and other pancreas-specific Cre alleles, such as Ptf1a-
Cre (also called p48-Cre), can also be used to drive tumour
development in the pancreas.
In this section, we discuss how the KPC model is utilised in both
chemopreventive and interventional settings, which are designed to
address different clinical questions (Fig. 3). Chemoprevention
studies aim to evaluate the effects of dietary compounds or
therapeutic agents that can prevent tumour initiation or that can slow
or arrest tumour development. They also include epidemiological
studies to identify factors that can increase or reduce the risk of
developing cancer. By contrast, interventional studies are designed
to evaluate the effect of a treatment – or treatment combinations – on
tumour progression and metastasis (early intervention studies) or on
established tumours (late intervention studies). They are thus
relevant for identifying treatments that can reverse, slow or arrest
cancer once it is fully established.
Chemoprevention
Several chemoprevention studies have been conducted in the
LSL-KrasG12D; Pdx1-Cre (KC) model, in which oncogenic Kras
alone is expressed in the pancreas, as well as in KPC mice. In this
setting, mice with early-onset pancreatic disease (generally
consisting of early-stage PanIN) are treated very early and prior to
the onset of final-stage PDAC. In published studies, the age at
enrolment varies from weaning to 10 weeks in KC mice and from
weaning to 6 weeks in the KPC model, and the effect of a treatment
is assessed either at pre-determined time points (to evaluate the
effect on cancer initiation) or at the disease end point (to evaluate the
effect on overall survival) (Bai et al., 2011; Chugh et al., 2012;
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Fig. 3. Enrolment scheme for chemoprevention and intervention studies in KPCmice. In preclinical studies using LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre
(KPC) mice, different approaches are used to address different clinical questions. Grey arrows indicate no intervention; green arrows indicate pre-treatment
monitoring; and blue arrows indicate treatment assessment. (A) Chemoprevention studies aim to evaluate dietary compounds or therapeutic agents that
prevent tumour initiation or slow/arrest tumour development. Mice are enrolled between weaning and 6 weeks of age and, at this stage, usually present with
early-stage PanIN. Treatments can be assessed at pre-determined time points or can continue until end point (to evaluate survival). (B) In early intervention
studies, which are used to test anti-metastatic therapies, treatment is initiated when mice are 10-12 weeks old, when they commonly have early and late
PanINs and occasional tumours. Treatment can last for a fixed period or can continue until end point. (C) Later intervention studies are performed on
animals bearing established tumours and are thus relevant for identifying treatments that can reverse, slow or arrest cancer once fully established. These
studies require more elaborate monitoring of mice, including manual palpation and ultrasound to monitor tumour size and progression. Treatment can begin
when tumours reach the enrolment size for a study. Depending on tumour size, treatment can be short (9-11 days) or long (up to 45 days) (see main text for
more detail). (D) Optimal design for intervention studies in KPC mice, incorporating serial sampling to allow pre- and post-treatment assessments of tumour
and blood samples.
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Husain et al., 2013; Keenan et al., 2014; Lampson et al., 2012; Li
et al., 2013; Liao et al., 2013; Morton et al., 2010b; Plentz et al.,
2009; Yip-Schneider et al., 2013). For example, KPC mice have a
lower tumour burden and increased survival time when treated from
4 weeks of age with atorvastatin, a cholesterol-lowering competitive
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG CoA)
reductase (Liao et al., 2013). A similar outcome was seen when
treatment was initiated at 5 weeks of age with sulindac, a non-
steroidal anti-inflammatory drug (NSAID), which is an inhibitor of
aldo-keto reductase family member 1B10 (AKR1B10), a protein
that is overexpressed in human PDAC (Li et al., 2013). The
favourable results reported in these two studies might have been
caused by the inhibition of PanIN progression. However, later
disruption of tumour development and maintenance, or a
continuous effect throughout the disease process, cannot be ruled
out and further work is needed to dissect these effects.
Epidemiological experiments have also been performed in the
KPCmodel and in other GEMMs, including analysis of the effect of
diet, nicotine and aspirin on tumour development (Hermann et al.,
2014; Lanza-Jacoby et al., 2013; Philip et al., 2013). Nicotine
administration accelerates Kras-induced PanIN progression in the
pancreas, with increased proliferation in PanIN in nicotine-treated
mice. Mechanistically, nicotine results in the activation of Akt-
ERK-Myc signalling and the subsequent downregulation of Gata6
(Hermann et al., 2014). Intermittent and chronic calorie restriction
in the KC model decreases PanIN progression, with fewer PanIN-2
and PanIN-3 lesions observed. Proliferation in PanIN was also
significantly reduced as a consequence of calorie restriction (Lanza-
Jacoby et al., 2013). Conversely, a high-fat diet increased stromal
content and accelerated pancreatic tumour progression, with
cyclooxygenase-2 (Cox2) playing an important role in this
process (Philip et al., 2013).
Early intervention
Early intervention studies are carried out on mice of a fixed age,
without predetermining whether or not they have advanced
tumours. Mice are generally enrolled on a study between 10-
12 weeks of age (Plassmeier et al., 2013). At this stage, most KPC
mice in a cohort would not have advanced PDAC but instead a mix
of early and late PanINs and occasional tumours. Treatment in this
setting generally occurs for longer periods of time relative to
treatment in late intervention studies, and can continue until the
disease end point, or for a fixed period of time after which the mice
are allowed to age with no further intervention. These early
intervention studies thus provide a means to test for drugs that can
prevent metastases formation. This is not possible using late
intervention protocols, when metastases have already developed.
Xenograft ‘metastasis’ models also cannot be used for such tests
because they do not recapitulate the stroma that characterises
pancreatic cancer, which likely contributes to the metastatic
phenotype.
Early intervention studies can also provide insight into the
pathways that are important for PDAC initiation and development,
and, additionally, can help us to understand whether the early
perturbation of signalling pathways affects metastasis. For example,
the inhibition of Src kinase with Dasatinib, a drug used in some
forms of leukaemia, with treatment beginning in 70-day-old
KPC mice until disease end point, significantly decreased the
formation of metastases, albeit without an effect on primary tumour
growth or overall survival. Thus, although it might not prevent
primary tumour progression, Src inhibition represents a potential
anti-metastatic strategy for treating PDAC (Morton et al., 2010b). In
another study, treatment of 70-day-old KPC mice with a LOX-
blocking antibody decreased tumorigenesis in combination with
gemcitabine, and decreased metastatic burden (Miller et al., 2015).
Treatment of KPC mice from 8 weeks of age with the smoothened
inhibitor IPI926 demonstrated that long-term inhibition of
hedgehog signalling actually accelerates tumour development and
decreases survival (Rhim et al., 2014), whereas treatment of KPC-
Brca1 mice at the same time point with the DNA demethylating
drug 5-aza-2′-deoxycytidine (decitabine) significantly inhibited
tumour growth (Shakya et al., 2013). However, one important
consideration is that early intervention studies involve extended
treatment, often prior to the existence of frank carcinoma. Tumours
developing under these circumstances might evolve to circumvent
inhibition, and therefore might be different molecular and biological
entities to the tumours that form in untreated mice. Therefore, a
favourable outcome in this setting does not indicate that the therapy
will successfully inhibit an established tumour, and experiments
with promising agents might need to be repeated in a late
intervention setting.
Given that many pancreatic cancer patients die from distant
metastases even after surgical removal of primary tumours
(Heinemann and Boeck, 2008), it is important to test anti-
metastatic therapies under these conditions. Thus, we and others
are now trialling the excision of primary tumours from the pancreas
of mice in order to improve our testing of anti-metastatic therapies;
these studies are still at an early stage.
Later intervention
As previously mentioned, at the time of diagnosis, individuals with
PDAC usually present with late-stage carcinoma. Thus, in
evaluating a novel cancer therapy or therapy combination, it is
important to assess efficacy on already established tumours, either
in terms of survival or by clinical and molecular parameters. In
preclinical settings, this requires the identification of tumour-
bearing mice prior to the initiation of treatment. The KPCmodel has
a variable latency, which necessitates the use of manual palpation
and non-invasive imaging modalities, both to identify animals that
carry tumours and to determine tumour size. The schema in Fig. 3C
outlines the typical monitoring and screening of KPC mice in late
intervention studies (Sastra and Olive, 2013). Beginning at
approximately 2 months of age, mice are manually palpated
weekly to detect any masses in the abdomen and, with
experience, tumours as small as 2 mm or less can be identified by
this method. When a mass is detected by palpation, high-resolution
ultrasound is used to confirm the presence of a tumour and to
measure its size. Ultrasound can also be used to follow tumours over
the course of treatment, and volumetric measurements can be
performed to establish whether tumour growth is altered in response
to therapy (Sastra and Olive, 2013). Treatment can begin when
tumours reach a size that makes a mouse eligible for enrolment into
a late intervention study.
Several therapeutic studies have been published using KPC mice
with different approaches to target tumours (Beatty et al., 2011;
Cook et al., 2012; Courtin et al., 2013; Frese et al., 2012; Jacobetz
et al., 2013; Neesse et al., 2013; Olive et al., 2009; Provenzano et al.,
2012). Mice enrolled in these studies had varying tumour sizes,
between 2-10 mm in diameter, with intervention beginning when
tumours are 2-5 mm, 4-6 mm, 6-9 mm or 5-10 mm for individual
studies published. The Hedgehog (Hh) and Notch signalling
pathways are two developmental pathways that are activated in
pancreatic cancer. When these signalling pathways are inhibited in
the KPC model, in combination with treatment with gemcitabine,
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the mice have improved survival relative to controls, although the
mechanism of action differs between the two pathways. The
inhibition of Hh signalling decreased the stromal content of KPC
tumours, effectively increasing the delivery and/or efficacy of
gemcitabine (Olive et al., 2009). By comparison, the inhibition of
Notch signalling seemed to induce vascular regression, causing
tumour hypoxia and widespread necrosis, even in the absence of
improved gemcitabine delivery (Cook et al., 2012).
Targeting the stromal component, either by depleting the
extracellular matrix component glycosaminoglycan hyaluronic
acid (HA) or by inhibiting the matrix protein CTGF (connective
tissue growth factor), was also effective in combination with
gemcitabine. Whereas HA depletion by PEGPH20 resulted in
improved vasculature and increased gemcitabine delivery, blocking
CTGF decreased the expression of the pro-survival protein XIAP
(X-linked inhibitor of apoptosis) and induced the killing of tumour
cells (Jacobetz et al., 2013; Neesse et al., 2013). The depletion of
HA described for the treatment of larger tumours has also been
tested in tumours of 2-5 mm diameter, and has similarly improved
survival in combination with gemcitabine (Provenzano et al., 2012).
PEGPH20 is currently being assessed in a randomized Phase 2
clinical trial assessing its efficacy as a first-line therapy against
metastatic pancreatic cancer in combination with gemcitabine/nab-
paclitaxel compared to gemcitabine/nab-paclitaxel alone (https://
clinicaltrials.gov/ct2/show/NCT01839487). PEGPH20 initially
proved problematic clinically, with a high rate of blood clots and
other thromboembolic events observed in the PEGPH20 arm.
Following a protocol amendment, the interim data from the trial was
recently revealed to be promising, with increased median
progression-free survival and overall response rate in the
PEGPH20 arm compared with the gemcitabine/nab-paclitaxel
arm. There was also a trend towards improvement in median
overall survival (http://www.halozyme.com/Investors/News-
Releases/; News Release on 31st May 2015).
In another preclinical study, the efficacy of nab-paclitaxel was
assessed in combination with gemcitabine in a limited-duration
experiment (Frese et al., 2012). In this study, nab-paclitaxel
effectively altered gemcitabine metabolism by decreasing the levels
of the primary gemcitabine-metabolizing enzyme, cytidine
deaminase (CDA). This increased gemcitabine stability and,
uniquely, it induced tumour regression (Frese et al., 2012).
Another approach to targeting PDAC involves the immune
system. Administration of AMD3100, a C-X-C chemokine receptor
type 4 (CXCR4) inhibitor, in combination with the inhibitory
checkpoint antagonist anti-PD-L1 (anti-programmed death 1 ligand
1), results in the loss of p53-positive tumour cells and in the
accumulation of CD3+ T-cells (see Box 2) in the tumour area (Feig
et al., 2013). In another study, the immune system was modulated
using a CD40 agonist. The resulting tumour shrinkage was
mediated by macrophages, and the expected influx of T cells into
the tumour did not occur (Beatty et al., 2011). Further work showed
that tumour-derived granulocyte-macrophage colony stimulating
factor (GM-CSF) regulates the recruitment of Gr-1+CD11b+
myeloid cells, which suppress antigen-specific T-cell responses
(Bayne et al., 2012). These studies exemplify a few of the many
approaches that are being considered in the targeting of PDAC,
including combinatorial approaches that target tumour cells and the
individual components of the stroma.
Established tumours in the KPC model undergo rapid growth.
With tumours of 5-10 mm diameter, the median survival of
untreated mice is around 9-11 days. As a consequence, treatment
regimens tend to be of a limited duration, even where combination
treatments induce a statistically significant increase in survival.
Short-term studies can also be carried out with fixed durations of
treatment. These enable in-depth mechanistic analyses of the
therapeutic effects of a given treatment, but might also be useful in
cases where longer-term treatment is not feasible. Nab-paclitaxel,
for instance, is formulated using human albumin and induces
anaphylaxis in mice, thereby necessitating short-term treatment
(Frese et al., 2012). In general, using smaller tumours tends to
lengthen the treatment period and consequently drug exposure. For
instance, with tumours of 2-3 mm diameter, the median survival of
untreated mice is approximately 45 days (Provenzano et al., 2012).
This approach permits the long-term effects of drug exposure to be
assessed, both on the tumour and on the host, which is not possible
in mice with larger tumours. This also models the condition of
individuals who present at an early stage at the clinic.
Factors that influence response to therapy
Irrespective of tumour size, interventional approaches are generally
labour- and resource-intensive, requiring a large mouse colony and
a substantial investment of time to screen and monitor treated
animals. Particularly in the case of large tumours, mice are also lost
to ill health prior to enrolment, thereby extending the enrolment
period, and in fixed-duration experiments, mice that do not reach the
required time point owing to short survival times need to be
replaced.
When assessing responses to therapeutic agents, varying results
can be obtained depending on tumour size. There is a lack of studies
examining the differences in tumour response based on initial
tumour size. However, our preliminary observations suggest that, in
KPC mice with tumours of 6-9 mm diameter at the time of
enrolment in the study, the tumour growth in the first 7 days post-
enrolment correlates with survival, perhaps indicating that 7 days is
a useful time point to assess early responses to treatment. As another
example, there is generally not a significant difference in survival
between vehicle- and gemcitabine-treated cohorts in KPC mice
with large tumours (Olive et al., 2009). However, when mice
with smaller tumours (3-6 mm mean diameter) are treated with
gemcitabine, and compared to vehicle-treated controls, gemcitabine
seems to have a beneficial effect on their survival (Fig. 4). This
might be due to poor drug perfusion in large tumours because of
Vehicle (n=12, 19 days)
Gemcitabine (n=12, 25 days)
0 20 30 40 50
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Fig. 4. Effects of tumour size on response to treatment in the KPCmodel.
Gemcitabine imparts a small yet significant survival benefit in micewith smaller
tumours (our unpublished observations). Mice were enrolled on study when
tumours reached 3-6 mm mean diameter. Mice were treated with either saline
or gemcitabine (100 mg/kg body weight) intraperitoneally twice per week until
end point. 12 mice were enrolled per cohort. The median survival post-
enrolment is indicated for each cohort in the figure. The Log-rank test was
conducted using GraphPad Prism (P=0.0236).
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their well-developed desmoplastic stroma (Olive et al., 2009).
Another example of differing outcomes is seen with the use of the
matrix-depleting agent PEGPH20, which was independently
assessed in the two studies involving mice with large or small
tumours mentioned above (Jacobetz et al., 2013; Provenzano et al.,
2012). In combination with gemcitabine, PEGPH20 improved
survival in both circumstances but with some differences. Smaller
tumours (2-5 mm diameter) were characterized by a significant
remodelling of their stroma, including a depletion of fibrillar
collagen and α-smooth muscle actin (α-SMA)-positive fibroblasts.
By contrast, the stromal content of larger tumours at end point
remained similar between the control and treated groups. These
findings suggest that primary tumour burden is not the sole
determinant of treatment outcome and that this outcome can be
influenced by the presence of a well-established tumour stroma.
Other factors that might affect therapeutic outcome and survival
include tumour location, extent of metastatic disease and occurrence
of cachexia (Bachmann et al., 2008; Neoptolemos et al., 2004;
Watanabe et al., 2004), which together reflect the complex and
multifaceted nature of advanced pancreatic cancer.
Duration of treatment can also affect therapeutic outcome. As
previously described, Hh pathway inhibition was first reported to
decrease stromal content in KPC mice with large tumours, thereby
increasing gemcitabine delivery to tumours and extending survival
when administered in combination with gemcitabine (Olive et al.,
2009). Unfortunately, despite a promising Phase 1 clinical trial, these
results were not borne out by the Phase 2 study. Following the failure
of this clinical trial, further work was carried out in the KPCmodel to
understand the discrepancy. In this study (Rhim et al., 2014), mice
were treated for an extended period of time, and the preclinical data
recapitulated what was seen in the clinic, with inhibition of Hh
signalling decreasing survival rather than improving it. This indicates
that the prolonged inhibition of signalling pathways might have
different effects to those intended, which would not be picked up by a
‘large tumour’ intervention study (Rhim et al., 2014). Given the
shorter treatment duration in mice with large tumours, apparent
treatment outcomes might simply be indicative of acute responses of
tumours to therapy (in the case ofHh inhibition, the initial depletion of
the stroma and the corresponding increase in gemcitabine delivery to
tumours). In reality, extended exposure to compounds might be
required to unveil the consequences of a treatment’s indirect effects or
the development of resistance through the modulation of signalling or
by other mechanisms.
The genetic background and the specific genetic alterations of the
mice that are used in a study are two other factors to consider when
evaluating response to therapy. As has been discussed earlier, the
outcome of genetic and therapeutic studies can vary depending on
the underlying genetic alterations in the mouse models.
Understanding these differences, and identifying cohorts that are
likely to respond to a given therapy, might inform the selection of
patient populations in clinical trials.
Translatingmechanistic information frommice to humans: limitations
and opportunities
Improving success rates in clinical trials depends on the use of
robust and predictive preclinical models. Owing to its genetic and
histopathological similarity to human PDAC, the KPC model is
relevant for evaluating therapies and for understanding treatment
mechanisms. However, the examples mentioned above illustrate the
importance of determining the best way of using preclinical models,
so that the obtained results accurately reflect clinical outcome.
Results obtained from studies using the KPC model suggest that
mice bearing smaller tumours might be of particular relevance for
survival studies because their use allows sufficient time for adverse
effects to become apparent. Care must also be taken when
interpreting the results of such studies, in particular focusing on
change in tumour volume and not absolute tumour size.
Another important question that requires consideration is whether
the tumour at the end of the treatment period is the same biological
entity as the initial tumour at the start of the study. Until now,
tumour comparisons have been static and carried out between
treatment cohorts (e.g. vehicle versus drug) because it has not been
possible to obtain pre- and post-treatment tumour samples.
Recently, however, a laparotomy (see Box 2) method has been
developed that allows tumour biopsies to be obtained surgically
(Sastra and Olive, 2014) from KPC tumours. This technique allows
the paired comparison of pre- and post-treatment samples, for
example, to analyze whether the continued accumulation of
mutations alters the activity of signalling pathways targeted by
drugs. This technique might also enable biopsies to be obtained and
examined prior to, during and after treatment, and then compared to
determine how a tumour is modulated by treatment and whether it
remains the same entity in terms of its histopathology and signalling
pathways. Although this approach might remove the need to use
large cohorts to account for inter-tumour heterogeneity and
biological variation, small individual biopsies might not be
representative of the entire tumour due to heterogeneity.
A key strength of preclinical models is the ability to gain
mechanistic insight into the tested therapies, in a manner that would
not be possible in a clinical setting. For example, fixed-time-point
pharmacodynamic studies can be conducted, allowing the immediate
(24-48 h), intermediate (7 days) and long-term effects of treatment to
be compared, for example on signalling pathways and tumour
characteristics such as proliferation, apoptosis, etc. Therapies that
target metastasis can be tested in early and advanced disease, and the
effect of drugs on organs other than the pancreas can be assessed.
Haematological and biochemical analyses can complement
molecular investigations both in pharmacodynamic and survival
studies. Routine imaging including high-resolution ultrasound as
discussed above, but also magnetic resonance imaging (MRI),
positron emission tomography and micro-computed tomography, can
be carried out to evaluate tumour progression and dissemination.
Preclinical testing inGEMMs also has the potential to identify tumour
biomarkers that can be used to either predict drug response or to
stratify patients for treatment (Singh et al., 2012).
In addition to targeting the primary tumour and disseminated
disease, studies can be conducted on symptoms, such as cachexia,
which are associated with PDAC. The importance of the stroma and
immune compartments in tumours can also be investigated. Recent
work has, in fact, shown that the stromal compartment in PDAC
might have a role in suppressing pancreatic tumours (Ozdemir et al.,
2014; Rhim et al., 2014); however, careful interpretation of data is
required when tumours are initiated in the absence of stroma, or
where depleting the stroma results in a substantial inflammatory
response. As mentioned above, there are also several approaches for
targeting the immune system that are being explored to enhance the
anti-tumour immune response, such as activation of CD40,
inhibition of chemokine (C-X-C motif ) ligand 12 (CXCL12) and
vaccines (Beatty et al., 2011; Feig et al., 2013; Keenan et al., 2014).
Given that chemotherapy is a mainstay of PDAC treatment,
combinations with chemotherapy should be considered when
assessing new drugs preclinically. Indeed, most preclinical work
to date has focused on the use of gemcitabine in combination with
various agents. The changing landscape of treatment in the clinic
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necessitates the need for a more up-to-date approach to
chemotherapy in the preclinical models. The FOLFIRINOX
regimen might be challenging to model in mice, but new
therapies can be tested in combination with gemcitabine/nab-
paclitaxel to further develop current treatments.
Despite their advantages, GEMMs have several drawbacks,
including the length of time needed to generate mutant mice
carrying several genetic alterations. In conditional GEMMs, such as
the KPCmodel, genetic alterations are often activated simultaneously
in a large number of cells during development in the mouse, even
though they are used as models of sporadic, non-inherited human
cancers. In addition, models such as KPC mice cannot be used to
study the cell-of-origin of pancreatic cancer. This has required the use
of alternative promoters, such as the inducible tetracycline-inducible
Elastase-cre or the Nestin promoter (Guerra and Barbacid, 2013).
Tissue-specific promoters, such as Pdx1-cre, are sometimes
expressed in other tissues, resulting in off-target pathologies, such
as papillomas and lymphoma. Tumour development in GEMMs can
also take a long time and occurs with variable latency. Unlike
xenografts, tumour monitoring might require advanced imaging,
including high-resolution ultrasound and MRI. Although useful
information can be obtained from these imaging modalities, they
require specialist training and equipment that is not always easily
available. In all, preclinical testing in GEMMs is significantly more
expensive than the testing performed in in vitro culture or xenografts.
Nevertheless, their advantages, as discussed here, make them a very
promising preclinical platform, and a potential means of assessing
complex treatment modalities and of identifying anti-cancer drug
combinations to evaluate in the clinic.
Conclusions
Owing to their similarity to human disease, KPC mice and other
GEMMs of pancreatic cancer can be excellent tools to assess
therapeutics and to understand mechanisms of drug action and
resistance in tumours. They have not yet been completely validated
in terms of their ability to predict the outcome of trials; however,
as discussed in this Review, there is extensive evidence of their
relevance in preclinical research (Singh et al., 2010). In order to
remain clinically relevant, preclinical testing in these models must
keep abreast of developments in the clinical sphere. GEMMs might
also provide information relevant for patient stratification in clinical
trials. If we are to derive benefit from these models, consideration
must be given to the way in which they are used, including the
timing and scheduling of treatment, because this might affect
experimental outcomes and therefore the predictive accuracy of the
model. Any insight gained from such preclinical models must be
extended to the clinic to demonstrate their relevance. The models
that are currently available are relevant; however, they will become
more predictive of clinical outcomes as we gain more knowledge
and understanding of the various factors that affect response to
therapy. In the future, it is likely that more attention will be paid to
the model used in preclinical testing, the stage of intervention and,
importantly, what constitutes a response that is robust enough to
provide confidence for translation to the clinic.
This article is part of a subject collection on Model Systems in Drug Discovery: from
Bench to Patient. See related articles in this collection at http://dmm.biologists.org/
cgi/collection/drugdiscovery
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